ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 251 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $210,590 | -68.1% | 13,228 | -67.3% | 0.01% | -74.4% |
| Q3 2022 | $661,000 | +130.3% | 40,394 | +98.2% | 0.04% | +200.0% |
| Q2 2022 | $287,000 | -41.9% | 20,383 | 0.0% | 0.01% | -35.0% |
| Q1 2022 | $494,000 | -4.6% | 20,383 | -8.1% | 0.02% | +11.1% |
| Q4 2021 | $518,000 | +100.8% | 22,186 | +43.0% | 0.02% | +125.0% |
| Q3 2021 | $258,000 | +214.6% | 15,515 | +386.7% | 0.01% | +300.0% |
| Q1 2021 | $82,000 | -85.2% | 3,188 | -69.3% | 0.00% | -83.3% |
| Q4 2020 | $554,000 | +78.7% | 10,369 | +38.0% | 0.01% | +71.4% |
| Q3 2020 | $310,000 | +109.5% | 7,516 | +145.5% | 0.01% | +133.3% |
| Q2 2020 | $148,000 | -81.7% | 3,062 | -84.0% | 0.00% | -84.2% |
| Q1 2020 | $807,000 | -12.3% | 19,102 | -11.2% | 0.02% | -9.5% |
| Q4 2019 | $920,000 | +43.5% | 21,506 | +20.7% | 0.02% | +40.0% |
| Q3 2019 | $641,000 | +21.6% | 17,821 | -9.7% | 0.02% | +25.0% |
| Q2 2019 | $527,000 | – | 19,732 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |